SteadyMed and the Pulmonary Hypertension Association Launch Campaign to Highlight Unique and Inspirational Faces Behind PH

SAN RAMON, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has launched the PHenomenal campaign, which gives people with PH and their loved ones the opportunity to submit photos and videos of themselves showing what makes them interesting and inspiring. To learn more about PH and the PHenomenal campaign, please visit

“My patients with PH continually impress me with their strength, humor and optimism. PH can be a devastating disease, but they refuse to let it define them,” said Dr. Fernando Torres, Professor of Internal Medicine at UT Southwestern Medical Center, where he serves as Medical Director of the Lung Transplant Program and head of the Pulmonary Hypertension Program.*

To participate in the PHenomenal campaign, people are encouraged to use #PHenomSelf to tag photos or video on their Tumblr, Instagram, Facebook and Twitter pages. People can also learn more about the campaign and see other submissions on the campaign’s Tumblr ( and Instagram ( pages.

PH is a condition defined as high blood pressure in the lungs. One form of PH, pulmonary arterial hypertension (PAH), is a progressive and life-changing chronic disease. Symptoms, which worsen over time and significantly impact patients’ lives, can include shortness of breath, dizziness and fatigue. There is no cure for the disease, which can become life-threatening within a few years if left untreated.

“I have been involved with the PH community for more than 22 years, since my daughter Meaghan was first diagnosed. Since then, I’ve had the privilege to meet many others who continue to amaze and inspire me,” said Carl Hicks, Executive Vice President of the PHA. “I remember Meaghan, who we lost in 2009, as vibrant, joyful and strong, and I am delighted that we are giving others the opportunity to show what makes them unique as well.”

“SteadyMed is committed to honoring the amazing and resilient people who comprise the PH community, and we couldn’t be prouder to be partnering with the PHA to give those with PH and their loved ones an opportunity to share their incredibly inspiring stories,” said Marylyn Rigby, Senior Director, Investor Relations and Marketing of SteadyMed.

*Dr. Torres is a paid consultant for SteadyMed.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed, please visit

About The Pulmonary Hypertension Association

Headquartered in Silver Spring, Md., with a growing list of chapters across the country, the Pulmonary Hypertension Association (PHA) is the country’s leading pulmonary hypertension organization. Its mission is to extend and improve the lives of those affected by PH; its vision is a world without PH, empowered by hope. PHA achieves this by connecting and working together with the entire PH community of patients, families and medical professionals. Among its programs, PHA facilitates more than 245 support groups around the country and delivers continuing education for medical professionals through PHA Online University. For 13 consecutive years, PHA has received the highest rating — four stars — for financial health and fiscal accountability & transparency from Charity Navigator, placing it in the top half of one percent of all rated charities. For more information, please go to, @PHAssociation on Twitter and on Facebook.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning the company's ability to advance its development-stage product candidates, including Trevyent, statements about the potential benefits of our development-stage product candidates and our PatchPump technology, and statements about our ability to obtain and maintain regulatory approval of our development-stage product candidates. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that Trevyent does not demonstrate clinical superiority to existing parenteral treprostinil products, that Trevyent is not approved for commercialization by the FDA, that Trevyent is not granted orphan drug exclusivity, and the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q filed on November 12, 2015. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

Contact: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999

Source: SteadyMed Therapeutics